<DOC>
	<DOCNO>NCT00502593</DOCNO>
	<brief_summary>The present study design evaluate child ( age 3 9 year ) immunogenicity safety different antigen dos candidate vaccine ( GSK1562902A ) administer follow two-administration schedule ( 21 day apart ) . Subjects control group receive Fluarix . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Evaluate Safety &amp; Immunogenicity Pandemic Influenza Vaccine ( GSK1562902A ) Children</brief_title>
	<detailed_description>This 107066 study participate study broad NCT00502593 study , include 2 study , 108498 108500 study . The NCT00502593 study stagger design ( subject group enrol sequentially 2 age stratum , ' 6-9 year ' 1st , ' 3-5 year ' next ) run 3 phase , phase A ( Study 107066 ) , B ( Study 108498 ) C ( Study 108500 ) . In phase , decision vaccinate subject age 3-5 year administer 2nd injection subject age 6-9 year make base safety data collect Days 0-6 1st injection subject age 6-9 year . Decision start Phase B make complete safety data include collected Day 28 Phase A ( 7 day 2nd injection ) age group . A similar approach use start Phase C. As safety data Phase A raise safety concern , Phases B C run parallel .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children investigator believe parents/guardians comply requirement protocol . Children age include 3 9 year age time first vaccination . Written inform consent obtain parent ( ) guardian subject . Healthy child establish medical history clinical examination enter study . Subjects likely reside vicinity study center duration study . Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) investigational vaccine within 30 day prior enrolment study , plan use study period . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration vaccine foreseen study protocol 30 day second vaccination , exception routine childhood inoculation delay , must administer day investigational vaccine candidate . Administration interpandemic influenza vaccine 21 day prior Day 0 Day 51 . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior enrolment study . Any chronic drug therapy continue study period , exception inhalative treatment seasonal allergy asthma . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Acute chronic clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history physical examination . History hypersensitivity vaccine . History allergic disease reaction likely exacerbate component vaccine use study . History neurological disorder seizure . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month prior enrolment study plan study . Any condition , opinion investigator , render subject unfit participation study</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Pandemic Influenza Vaccine ( GSK1562902A )</keyword>
</DOC>